Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Capital Expenditures (2016 - 2025)

Ligand Pharmaceuticals' Capital Expenditures history spans 15 years, with the latest figure at $74.5 million for Q3 2024.

  • For Q3 2024, Capital Expenditures rose 15195.07% year-over-year to $74.5 million; the TTM value through Jun 2025 reached $74.5 million, up 5156.67%, while the annual FY2024 figure was $75.0 million, 2030.08% up from the prior year.
  • Capital Expenditures for Q3 2024 was $74.5 million at Ligand Pharmaceuticals, up from $511000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $74.5 million in Q3 2024 and bottomed at -$5.0 million in Q4 2021.
  • The 5-year median for Capital Expenditures is $229000.0 (2020), against an average of $4.4 million.
  • The largest annual shift saw Capital Expenditures plummeted 3687.12% in 2021 before it skyrocketed 15195.07% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$132000.0 in 2020, then tumbled by 3687.12% to -$5.0 million in 2021, then soared by 74.13% to -$1.3 million in 2022, then surged by 132.25% to $417000.0 in 2023, then soared by 17762.59% to $74.5 million in 2024.
  • Per Business Quant, the three most recent readings for LGND's Capital Expenditures are $74.5 million (Q3 2024), $511000.0 (Q2 2024), and $2000.0 (Q1 2024).